Kymera Therapeutics, Inc. vs Pfizer, Inc. — Stock Comparison
Q·Score Breakdown
5.8
Neutral
Overall
6.5
Neutral
Quality
Health
Growth
Valuation
Sentiment
KYMR
96% of 23 covering analysts have a positive rating.
⚠ low return on equity (-27%).
PFE
Strong profitability with 12% net profit margins.
⚠ analyst sentiment is cautious.
Analyst Consensus
BUY
Target $118.86 (+47.3%)
21 analysts
HOLD
Target $29.00 (+10.2%)
27 analysts
Fundamentals
KYMR
PFE
—
Trailing P/E
19.4×
-19.9×
Forward P/E
9.4×
0.0%
Profit Margin
12.4%
0.0%
Gross Margin
75.8%
-27.1%
ROE
8.9%
55.5%
Revenue Growth
-1.2%
—
Earnings Growth
—
—
Beta
0.39
—
Price / Book
—
$6.6B
Market Cap
$149.8B
$28 – $103
52-Week Range
$22 – $29
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →